Vertex Pharmaceuticals Incorporated: Leerink Partners Resumes Coverage With Outperform Rating; Target Price $594
VRTX•Related News
Einride partners with Nvidia to adapt DRIVE Hyperion platform for autonomous heavy-duty trucking
NVDA•
Neurocrine Biosciences, Inc. <NBIX.O>: RBC cuts target price to $187 from $198
NBIX•
Profusa stockholders voted to authorize potential reverse stock split amendment
PFSA•
Plains GP Holdings LP <PAGP.O>: Barclays Raises Target Price to $24 from $23
PAGP•
US stocks weekly: Rate reckoning
SPY•